Ultime notizie per Immutep (NASDAQ:IMMP) Azioni

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Immutep Limited - American Depositary Shares

Immutep Ltd

In a report released on September 9, Melissa Benson from Wilsons maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a price tar...

Immutep Ltd (PRRUF) Receives a Buy from Wilsons

Analyst Naureen Quibria of Capital One Financial assigned a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $8.00. Na...

Buy Rating for Immutep: Promising Developments in Oncology and Competitive Edge

Immutep (IMMP) has released an update. Immutep's latest clinical trial, TACTI-003, shows promising results for its novel immunotherapy, efti, when ...

Immutep's Efti Shows Promise in Cancer Therapy

Bell Potter analyst Thomas Wakim maintained a Buy rating on Immutep Ltd (PRRUF – Research Report) today and set a price target of A$0.70. The compa...

Immutep Ltd (PRRUF) Gets a Buy from Bell Potter

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Immutep (IMMP – Research Report). The associated price target ...

Buy Rating Affirmed for Immutep on Promising Efti Outlook Despite Mixed Study Interpretations

Immutep receives A$3.6M R&D tax incentive from French government

Immutep (IMMP) has released an update. Immutep Limited, a biotech firm pioneering LAG-3 immunotherapies, has completed patient enrollment for the P...

Immutep Advances Breast Cancer Immunotherapy Trial

Earnings week ahead: JPMorgan, Wells Fargo, PepsiCo, Delta Air Lines, and more

Immutep: Navigating The Bumps In The Road

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Gritstone Oncology (G...

Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)

ACCD

AEHR

APLD

BSET

BSVN

BYRN

DOGZ

EDUC

ETWO

EVGR

FAST

FNGR

GRTS

HELE

HIFS

IMMP

LOOP

NAPA

NEOG

NRIX

PRRUF

RELL

STBX

TLRY

UPXI

USGO

VLGEA

VOXX

WAFD

WKEY

Press Releases

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Quarterly Activities Report Q1 FY25

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anika Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

aTyr Pharma

Biomea Fusion

Editas Medicine

Fate Therapeutics

Genfit

ITeos Therapeutics

Kodiak Sciences

Lexeo Therapeutics

Lyell Immunopharma

Ocugen

Precigen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Poseida Therapeutics, Inc. - Common Stock

Poseida Therapeutics

Pyxis Oncology

Rezolute

TScan Therapeutics

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Baird

Capital One

Maxim Group

WIIM

Immutep shares are trading higher after the company announced the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, at the CTOS 2024 Annual Meeting.

Comments

Immutep

Notizie

Ultime notizie per Immutep (NASDAQ:IMMP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO